Year Founded
2021
Ownership
Private
Employees
~50
Therapeutic Areas
Infectious DiseasesOncologyCardiovascular
Stage
Commercial
Modalities
Protein therapeutics

Monod Bio General Information

Launched LuxSit Pro, the world's first commercially available de novo protein product. The company's biosensors can detect spike protein on COVID-19 virus, cancer receptors, and cardiac troponin.

Contact Information

Website
Primary Industry
Biotech
Corporate Office

Drug Pipeline

LuxSit Pro
Commercial
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Monod Bio's pipeline data

Book a demo

Key Partnerships

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Monod Bio Funding

Deal TypeDateAmountStatusStage
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Monod Bio's complete valuation and funding history, request access »

Monod Bio Investors

Matrix Capital Management
Investor Type: Venture Capital
Holding: Minority
Global Health Investment Corporation
Investor Type: Venture Capital
Holding: Minority
Cercano Management
Investor Type: Venture Capital
Holding: Minority
Investor Name
Investor Type
Holding
Investor Name
Investor Type
Holding
You're viewing 3 of 7 investors. Get the full list »